News

SCIENTURE Increases Access to Innovative Hypertension Treatment

SCIENTURE Increases Access to Innovative Hypertension Treatment

Expanded Access to Arbli™ for Hypertension

Expanded Coverage Reaches Over 100 Million Lives Across the U.S.

SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), is excited to announce significant progress in the availability of Arbli™ (losartan potassium) Oral Suspension. This innovative medication has recently been included in the formularies of several major national health plans, marking a crucial step in expanding patient access to effective treatments for hypertension.

With over 100 million lives now benefiting from this addition, Arbli™ represents a breakthrough in how patients can manage their health. This easy-to-use oral suspension formulation breaks barriers for individuals who prefer a liquid medication over pills, making treatment simpler and more accessible for everyone involved.

Arbli™, the first FDA-approved liquid formulation of losartan potassium, addresses the needs of patients who find it challenging to use solid dosage forms. The commitment SCIENTURE has shown toward enhancing patient care is commendable, as this medication not only offers a safe therapeutic option but is also designed with the patients' convenience in mind. The U.S. market for losartan itself is valued at around $256 million, highlighting the vital role of products like Arbli™ in the medication landscape.

Patient-Centric Perspectives on Arbli™

According to Narasimhan Mani, President and co-CEO of SCIENTURE, this formulary inclusion signals strong confidence from health plans in Arbli™ and the company’s products. "This is a real win for patients who deserve accessible and affordable treatment options. Health plans are now enabling better access to our medication, ensuring lower out-of-pocket costs for those enrolled," he stated.

Shankar Hariharan, Executive Chairman, and co-CEO added, "This step shows our commitment to improving health outcomes while aiming for sustainable growth. We are just beginning to pave the way for more patients across the country to access SCIENTURE’s range of products." Such affirmations resonate deeply within the healthcare community, as they underscore the emphasis on patient needs and improved health outcomes.

What Makes Arbli™ Unique?

Arbli™ stands out in the pharmaceutical market as a novel formulation of losartan. Unlike traditional solid forms, it is a ready-to-use oral suspension that eliminates the need for compounding, thus providing greater consistency in dosing and quality. The unique peppermint flavor adds an appealing touch for patients, making regular medication adherence easier. Plus, it boasts a shelf life of 24 months when stored at room temperature, making it practical for consumers.

Indications and Benefits

Arbli™ is recognized for its effectiveness in treating several conditions related to hypertension. These include:

  • Managing hypertension in adults and children older than six years, significantly lowering blood pressure and reducing the risk of cardiovascular events.
  • Reducing stroke risk in patients with hypertension who have left ventricular hypertrophy.
  • Addressing diabetic nephropathy in patients with hypertension and type 2 diabetes, enhancing not just treatment success but overall patient health.

Understanding Hypertension

Hypertension is a severe public health issue, affecting nearly half of U.S. adults. As one of the leading causes of cardiovascular diseases, it’s essential for individuals to manage their blood pressure effectively. Symptoms can often go unnoticed, making routine check-ups crucial. Factors contributing to high blood pressure include age, obesity, a sedentary lifestyle, and high sodium intake. With effective treatments like Arbli™, managing these risks becomes significantly more achievable.

Company Overview and Contact Information

SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) operates through its subsidiary, Scienture, LLC. The company specializes in developing pharmaceutical products that aim to fulfill unmet patient needs. SCIENTURE's dynamic approach combines innovation with commitment to enhanced healthcare solutions, which is especially evidenced by the launch of Arbli™.

For more information about their products and initiatives, you can reach SCIENTURE at:

SCIENTURE HOLDINGS, INC.
20 Austin Blvd
Commack, NY 11725
Phone: (866) 468-6535
Email: IR@Scienture.com

Frequently Asked Questions

What is Arbli™?

Arbli™ is a novel oral suspension of losartan potassium designed to provide an effective treatment for hypertension.

Who can use Arbli™?

Arbli™ is indicated for patients over six years old for managing hypertension and related conditions.

What sets Arbli™ apart from other hypertension medications?

It is the first FDA-approved liquid formulation of losartan that does not require compounding, making dosing easier and more reliable.

How does SCIENTURE plan to expand access to its medications?

SCIENTURE is focused on partnerships with healthcare providers and payors to enhance treatment access and affordability for patients.

How should Arbli™ be stored?

Arbli™ can be stored at room temperature and has a shelf life of 24 months from the manufacturing date.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

AI Innovation Incubator Shakes Up Shanghai's Lingang

Updated Category News Views 112

Incubator Conference Lights Up Lingang Hold onto your hats, folks! Shanghai's Lingang Center is buzzing with activity as the 'World Top-performing Incubator Conference 2026' kicks off. Taking place from October 26 to 28, this gathering isn't just another run-of-the-mill tech meet-up. Oh no, it's about redefining how we talk about innovation, incubation, and the future,...

Continue Reading
XCMG Lends Heavy Equipment to Nairobi Rescue Effort

Updated Category News Views 57

When Buildings Fall and Heavy Equipment Matters Buildings aren't supposed to just topple over. It's not some new trend I missed, but when it does happen, you've got a crisis – and that's exactly what unfolded in Nairobi on October 23 when an 18-story tower gave out, crashing down into chaos in the Eastleigh neighborhood. From Ground Zero to Immediate Response Imagine...

Continue Reading
Real-World Study Shows Viable Use of Tarlatamab

Updated Category News Views 0

Breaking New Ground in Cancer Care There's a shift happening in the realm of cancer treatment, and OneOncology's latest study on tarlatamab is right at the forefront. Bringing advanced therapies closer to home isn't just a pipe dream anymore. This real-world study, unveiled at the 2026 ESMO Congress, underscores that administering tarlatamab in outpatient settings might...

Continue Reading
Yuchai Eyes African Market Expansion with Strategic Visits

Updated Category News Views 49

Yuchai's Bold Move into Africa There's something gutsy about a company that doesn't just sit on its achievements but heads out into new territories. China Yuchai International (NYSE: CYD), a big player in powertrain solutions, recently embarked on a strategic tour across the African continent, a move that could well shape their future market playbook. East Africa:...

Continue Reading
Gilded Dragonfly Gallery: A Jewel in Brunswick's Crown

Updated Category News Views 22

There's something remarkable happening in Brunswick, Maryland. This small town's stirring to life with a splash of creativity, and it's just gotten a little brighter with the grand opening of the Gilded Dragonfly Gallery. This isn't just another art gallery popping up; it's a statement of transformation, from quiet exurbia to a thriving arts destination. Jayme Marshall:...

Continue Reading
Unlocking Airbnb Success: Expert Tips on Design Features

Updated Category News Views 0

Design's Role in Capturing Airbnb Guests Alright, folks, let's dissect what really gets those Airbnb bookings. Wendy Anguiano, no stranger to sprucing up coastal rentals, dishes the dirt on design elements that scream 'book me' on first click. She's hailed from Design & Dwell Homes, operating right from the heart of Santa Rosa Beach, Florida. It's a fierce market out...

Continue Reading
Canton Fair 2026: Tech and Tradition Transform Jewelry

Updated Category News Views 109

Tech-Savvy Elegance at Canton Fair Dive into the glitz and glamour of the jewelry zone at the 140th Canton Fair, where technology and craftsmanship are forging a new narrative for luxury accessories. This isn’t just your grandmother’s jewelry box we're talking about anymore. We’re witnessing the dawn of precious metal smart rings and dual-band smart watches that...

Continue Reading
Epilepsy Market's Explosive Growth Forecasted to 2036

Updated Category News Views 12

It's a wild world out there for epilepsy treatments—like a relentless bull run with everyone eyeing the prize. The latest buzz points to a fat 2036 forecast for this sector, driven by a mix of standout technologies and breakthrough therapies. You'd be a fool to blink and miss it. Rising Numbers Stir the Market The numbers, oh boy, they're climbing. In 2025, about 7...

Continue Reading
Medefy's New Award Honors Cost-Savvy Consultants

Updated Category News Views 11

Awarding Ingenuity in Healthcare Cost Containment Ditch the chatter, folks. Let’s talk about a little piece of news that just might be the ripple effect the healthcare sector needs right now. Medefy, that cost-containment whiz, has unleashed 'The Curve Bender Award.' Frankly, it's about time someone spotlighted the gritty work of benefits consultants grinding in the...

Continue Reading
IBSSC 2026: A New Chapter in Business Education

Updated Category News Views 50

Shifts in Business Education at the IBSSC 2026 Boy, oh boy, Shanghai was buzzing the other week. We’re diving into the heart of the 11th International Business School Shanghai Conference (IBSSC). There's a changing of the guard in how business education is viewed, and it was all happening from October 21 to 23 at the Xuhui campus of Shanghai Jiao Tong University. Global...

Continue Reading

Top 5 Most Recently Viewed Articles

LeoStella and BlackSky Propel Space Innovation through HALO

Updated Category News Views 130

LeoStella and BlackSky Join Forces for Space Development In a significant advancement in space technology, LeoStella has been chosen by the Space Development Agency (SDA) to participate in the Hybrid Acquisition for Proliferated Low-Earth Orbit (HALO) program. This project marks an exciting turn for nontraditional defense firms, allowing them to engage directly with SDA...

Continue Reading
Medical Care Technologies Implements Strategic Share Reduction

Updated Category News Views 94

Medical Care Technologies Initiates Share Reduction Plan Medical Care Technologies Inc. (MDCE) / Infinite Auctions has embarked on an important initiative to enhance its financial health and shareholder value by reducing the outstanding share count. This initial step involves slashing 200 million shares in what the company refers to as Phase One of this strategic plan....

Continue Reading
Innovent's Arcotatug Tavatecan: A Potential Game Changer

Updated Category News Views 14

Innovent's New Kid on the Block Alright, let's dive into the nitty-gritty of Innovent Biologics and their latest scientific marvel, arcotatug tavatecan. It's not every day you hear about a potential game-changer in the oncology world, but this CLDN18.2-targeted ADC seems to be creating quite the stir. For a company founded with the mission of making high-quality medicines...

Continue Reading
SolarBank Set to Announce Annual Results and Host Webinar Event

Updated Category News Views 87

SolarBank to Share Annual Financial Results SolarBank Corporation (CSE: SUNN, NASDAQ: SUUN) is preparing to unveil its annual financial results, an important occasion for both stakeholders and investors. Recently, the company announced it would release its results for the year ending June 30, 2024, following the close of trading on the Nasdaq market. An engaging webinar...

Continue Reading
Reviewing the Sprinklr Class Action Filing: What to Know for Investors

Updated Category News Views 235

Understanding the Class Action Lawsuit Involving Sprinklr, Inc. Investors today are continuously seeking secure avenues for their financial assets. However, events can unfold that may alter their initial expectations. The latest developments surrounding Sprinklr, Inc. (NYSE: CXM) have prompted an important class action announcement. This notice is crucial for shareholders...

Continue Reading